Pieris Pharmaceuticals Announces Merger and Share Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2024
0mins
Should l Buy ?
Source: Business Insider
Pieris Pharmaceuticals Announcement: Pieris Pharmaceuticals has approved a significant increase in authorized shares and the 2024 Equity Incentive Plan during a special stockholder meeting, alongside finalizing a merger with Palvella Therapeutics which will lead to a name change.
Company Overview: Operating in the biotechnology sector, Pieris focuses on developing therapeutic proteins, currently holds a market cap of $21.92M, and has a year-to-date price performance of 14.01%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
